{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+1+of+Aluminum+Adjuvant&page=2", "query": { "intervention": "Dose 1 of Aluminum Adjuvant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+1+of+Aluminum+Adjuvant&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+1+of+Aluminum+Adjuvant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T22:05:11.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03382418", "title": "Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp145 C.6980 Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2017-12-27", "completion_date": "2019-09-25", "has_results": true, "last_update_posted_date": "2021-10-08", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 3, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03382418" }, { "nct_id": "NCT04915768", "title": "Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CH505 TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-05-AF", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide suspension", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2023-01-23", "completion_date": "2025-07-15", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 3, "location_summary": "Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04915768" }, { "nct_id": "NCT00280033", "title": "H5 Adult - Chiron Study of Bird Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" }, { "name": "Inactivated Influenza A/H5N1 Vaccine (Chiron)", "type": "BIOLOGICAL" }, { "name": "MF-59", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 394, "start_date": "2006-02", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-09-13", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 4, "location_summary": "Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00280033" }, { "nct_id": "NCT02788045", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 201, "start_date": "2016-07-08", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788045" }, { "nct_id": "NCT06799494", "title": "HPV Vaccine Reduced Dose", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HPV" ], "interventions": [ { "name": "Gardasil-9", "type": "BIOLOGICAL" }, { "name": "Lidocaine injection", "type": "DRUG" }, { "name": "Lorazepam", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 100, "start_date": "2025-08-06", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799494" }, { "nct_id": "NCT05901636", "title": "A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza Prevention" ], "interventions": [ { "name": "INFLUENZA G1 mHA", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Al(OH)3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 170, "start_date": "2023-05-17", "completion_date": "2024-08-19", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 4, "location_summary": "Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05901636" }, { "nct_id": "NCT01666652", "title": "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dengue Fever" ], "interventions": [ { "name": "4 µg TDENV-PIV with Alum adjuvant", "type": "BIOLOGICAL" }, { "name": "1 µg TDENV-PIV with AS03B1 adjuvant", "type": "BIOLOGICAL" }, { "name": "Phosphate buffered saline", "type": "OTHER" }, { "name": "1 µg TDENV-PIV with Alum adjuvant", "type": "BIOLOGICAL" }, { "name": "1 µg TDENV-PIV with AS01E1 adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 100, "start_date": "2012-09", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01666652" }, { "nct_id": "NCT02685020", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 36, "start_date": "2016-03-28", "completion_date": "2019-01-03", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02685020" }, { "nct_id": "NCT03307915", "title": "A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "MVA-Mosaic", "type": "BIOLOGICAL" }, { "name": "Clade C gp140 + Mosaic gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 25, "start_date": "2018-03-05", "completion_date": "2021-11-05", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03307915" }, { "nct_id": "NCT00533741", "title": "SARS Coronavirus Vaccine (SARS-CoV)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronavirus (SARS-CoV)" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SARS-CoV", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-12-03", "last_synced_at": "2026-10-07T22:05:11.277Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533741" } ] }